Assertio Therapeutics (ASRT) Tops Q2 EPS by 4c ; Offers Guidance

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $30.7 million versus the consensus estimate of $30.19 million.

GUIDANCE:

Assertio Therapeutics sees FY2024 revenue of $110-125 million, versus the consensus of $120.6 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Occidental Petroleum releases Q2 2026 earnings considerations
• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• CORVEX (MOVE) files for 53.39M share offering by selling stockholders